$CRSP
CRISPR Therapeutics AG

2022 Q3 Form 10-Q Financial Statement

#000095017022015256 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $94.00K $158.0K $940.0K
YoY Change -88.59% -99.98% 74.4%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $65.86M $60.20M $58.67M
YoY Change 170.45% 101.96% 139.46%
% of Gross Profit
Research & Development $116.6M $123.2M $118.2M
YoY Change 10.73% 49.67% 67.44%
% of Gross Profit
Depreciation & Amortization $5.000M $7.300M $6.039M
YoY Change -5.66% 102.78% 122.43%
% of Gross Profit
Operating Expenses $182.5M $183.4M $176.9M
YoY Change 40.72% 32.83% 53.73%
Operating Profit -$182.4M -$183.3M -$176.0M
YoY Change 41.55% -124.03% 53.63%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $7.264M $3.544M $363.0K
YoY Change 559.76% 372.53% -81.43%
Pretax Income -$175.1M -$179.7M -$175.6M
YoY Change 37.09% -123.54% 55.97%
Income Tax -$600.0K $6.100M $3.600M
% Of Pretax Income
Net Earnings -$174.5M -$185.8M -$179.2M
YoY Change 37.27% -124.48% 58.37%
Net Earnings / Revenue -185690.43% -117616.46% -19065.64%
Basic Earnings Per Share -$2.24 -$2.40 -$2.32
Diluted Earnings Per Share -$2.24 -$2.40 -$2.32
COMMON SHARES
Basic Shares Outstanding 78.01M 77.51M 77.10M
Diluted Shares Outstanding 78.02M 77.51M 77.10M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $774.1M $880.2M $822.7M
YoY Change -48.14% -66.5% -49.22%
Cash & Equivalents $494.2M $496.9M $683.9M
Short-Term Investments $279.9M $383.3M $138.8M
Other Short-Term Assets $36.68M $41.65M $39.21M
YoY Change -11.45% 32.87% 50.82%
Inventory
Prepaid Expenses
Receivables $49.00K $66.00K $143.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.933B $2.107B $2.261B
YoY Change -23.27% -19.61% 23.37%
LONG-TERM ASSETS
Property, Plant & Equipment $166.1M $165.2M $157.5M
YoY Change 56.88% 119.05% 203.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $77.15M $8.392M
YoY Change
Other Assets $3.682M $3.760M $4.330M
YoY Change -23.1% -84.09% -81.42%
Total Long-Term Assets $420.7M $356.3M $345.6M
YoY Change 38.93% 27.9% 175.35%
TOTAL ASSETS
Total Short-Term Assets $1.933B $2.107B $2.261B
Total Long-Term Assets $420.7M $356.3M $345.6M
Total Assets $2.353B $2.463B $2.606B
YoY Change -16.6% -15.04% 33.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $32.11M $25.24M $27.11M
YoY Change 215.87% 148.83% 106.95%
Accrued Expenses $103.0M $82.22M $72.63M
YoY Change 50.73% 22.54% 45.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $150.9M $120.0M $113.7M
YoY Change 56.82% 20.05% 36.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.314M $6.092M $7.335M
YoY Change -34.28% -96.89% -89.42%
Total Long-Term Liabilities $5.314M $6.092M $7.335M
YoY Change -34.28% -96.89% -89.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $150.9M $120.0M $113.7M
Total Long-Term Liabilities $5.314M $6.092M $7.335M
Total Liabilities $399.4M $372.5M $361.3M
YoY Change 29.34% 25.97% 137.05%
SHAREHOLDERS EQUITY
Retained Earnings -$735.5M -$561.0M -$375.1M
YoY Change 1245.45%
Common Stock $2.712B $2.672B $2.637B
YoY Change 5.58%
Preferred Stock
YoY Change
Treasury Stock (at cost) $63.00K $63.00K $63.00K
YoY Change 0.0%
Treasury Stock Shares $180.3K $180.3K $180.3K
Shareholders Equity $1.954B $2.091B $2.245B
YoY Change
Total Liabilities & Shareholders Equity $2.353B $2.463B $2.606B
YoY Change -16.6% -15.04% 33.11%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$174.5M -$185.8M -$179.2M
YoY Change 37.27% -124.48% 58.37%
Depreciation, Depletion And Amortization $5.000M $7.300M $6.039M
YoY Change -5.66% 102.78% 122.43%
Cash From Operating Activities -$105.2M -$142.0M -$135.2M
YoY Change 29.37% -117.59% 34.35%
INVESTING ACTIVITIES
Capital Expenditures -$6.017M -$9.630M $15.35M
YoY Change -83.76% -66.15% 118.54%
Acquisitions
YoY Change
Other Investing Activities $93.48M -$46.44M -$99.17M
YoY Change -117.7% -82.49% -38.36%
Cash From Investing Activities $87.46M -$56.07M -$114.5M
YoY Change -115.48% -80.9% -31.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.11M 10.35M 10.65M
YoY Change 47.98% 22.61% -95.29%
NET CHANGE
Cash From Operating Activities -105.2M -142.0M -135.2M
Cash From Investing Activities 87.46M -56.07M -114.5M
Cash From Financing Activities 15.11M 10.35M 10.65M
Net Change In Cash -2.642M -187.7M -239.1M
YoY Change -99.58% -135.97% 461.8%
FREE CASH FLOW
Cash From Operating Activities -$105.2M -$142.0M -$135.2M
Capital Expenditures -$6.017M -$9.630M $15.35M
Free Cash Flow -$99.20M -$132.3M -$150.6M
YoY Change 124.03% -115.84% 39.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
1259000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Central Index Key
EntityCentralIndexKey
0001674416
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Entity File Number
EntityFileNumber
001-37923
dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
V8
dei Entity Address Address Line1
EntityAddressAddressLine1
Baarerstrasse 14
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6300
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Address City Or Town
EntityAddressCityOrTown
Zug
dei Entity Address Country
EntityAddressCountry
CH
dei City Area Code
CityAreaCode
41 (0)41
dei Local Phone Number
LocalPhoneNumber
561 32 77
dei Security12b Title
Security12bTitle
Common Shares, nominal value CHF 0.03
dei Trading Symbol
TradingSymbol
CRSP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78009260
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
496893000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
923031000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1568446000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1456098000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
66000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
305000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
41651000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
38079000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
2107056000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2417513000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
165194000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
137575000
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
8392000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
98000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
125000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12123000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16913000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
166740000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
174460000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3760000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5291000
CY2022Q2 us-gaap Assets
Assets
2463363000
CY2021Q4 us-gaap Assets
Assets
2751877000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
25244000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14816000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
82223000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91003000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1011000
CY2022Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
3953000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
724000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8267000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12158000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
270000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
171000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
119957000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
119883000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12323000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12323000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
234160000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
212872000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6092000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7339000
CY2022Q2 us-gaap Liabilities
Liabilities
372532000
CY2021Q4 us-gaap Liabilities
Liabilities
352417000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150347467
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77972479
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77170382
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77792163
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76990066
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
2420000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2391000
CY2022Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
180316
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
180316
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2669782000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2598114000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-560966000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-195915000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20342000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5067000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2090831000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2399460000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2463363000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2751877000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
158000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
900701000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1098000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
901240000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
123223000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82332000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
241468000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
153971000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26273000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28806000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
54294000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
52303000
CY2022Q2 crsp Collaboration Expense
CollaborationExpense
33922000
CY2021Q2 crsp Collaboration Expense
CollaborationExpense
26945000
crsp Collaboration Expense
CollaborationExpense
64568000
crsp Collaboration Expense
CollaborationExpense
46891000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
183418000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
138083000
us-gaap Operating Expenses
OperatingExpenses
360330000
us-gaap Operating Expenses
OperatingExpenses
253165000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-183260000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
762618000
us-gaap Operating Income Loss
OperatingIncomeLoss
-359232000
us-gaap Operating Income Loss
OperatingIncomeLoss
648075000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3544000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
750000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3907000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2705000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3544000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
750000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3907000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2705000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-179716000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
763368000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-355325000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
650780000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6118000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4143000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9726000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4718000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-185834000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
759225000
us-gaap Net Income Loss
NetIncomeLoss
-365051000
us-gaap Net Income Loss
NetIncomeLoss
646062000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-69000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-95000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
10000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3380000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-173000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15180000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-556000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-189283000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
759057000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-380326000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
645516000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.40
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
10.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.57
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77513327
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75826594
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77306970
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75418160
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.40
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.03
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77513327
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80449956
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77306970
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80458855
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1664234000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
222175000
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
3000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9784000
CY2021Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
751000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22092000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-378000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-113163000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1805498000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10909000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28331000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-168000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
759225000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2603795000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2399460000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
4000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10010000
CY2022Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
740000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25745000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11826000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-179217000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2244916000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10346000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24852000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3449000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-185834000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2090831000
us-gaap Profit Loss
ProfitLoss
-365051000
us-gaap Profit Loss
ProfitLoss
646062000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13308000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6368000
us-gaap Share Based Compensation
ShareBasedCompensation
50597000
us-gaap Share Based Compensation
ShareBasedCompensation
50423000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-9671000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4417000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-239000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2032000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9470000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8303000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13427000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1011000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-271000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
5865000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1148000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-5870000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-277195000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
706339000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24980000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35473000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
597136000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
715982000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
451529000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
289921000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-170587000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-461534000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
213267000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
21002000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
21167000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21002000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
234434000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-95000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-426875000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
479249000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
939944000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1185468000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
513069000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1664717000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5016000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7533000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
241000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
402000
crsp Leasehold Improvements Paid Directly By Landlord
LeaseholdImprovementsPaidDirectlyByLandlord
19252000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
496893000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1646646000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12123000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
18071000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
513069000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1664717000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
16000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5118000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1456098000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1978583000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
16000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
5119000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1973480000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
917800000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1311600000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, revenue recognition, equity-based compensation expense and reported amounts of expenses during the period. Significant estimates in these consolidated financial statements have been made in connection with revenue recognition and equity-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2022Q2 us-gaap Marketable Securities
MarketableSecurities
383300000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
405600000
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
113561000
CY2022Q2 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
3000
CY2022Q2 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
7000
CY2022Q2 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
113557000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1597081000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
20258000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1576838000
CY2022Q2 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1710642000
CY2022Q2 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
18000
CY2022Q2 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
20265000
CY2022Q2 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1690395000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
517383000
CY2021Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
1000
CY2021Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
517382000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1461200000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
78500000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
4600000
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
8400000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0.0
CY2022Q2 crsp Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year
DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear
0
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
216282000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
175382000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
51088000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37807000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
165194000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
137575000
CY2022Q2 us-gaap Depreciation
Depreciation
7300000
us-gaap Depreciation
Depreciation
13300000
CY2021Q2 us-gaap Depreciation
Depreciation
3600000
us-gaap Depreciation
Depreciation
6300000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13906000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23661000
CY2022Q2 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
52409000
CY2021Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
47986000
CY2022Q2 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
177000
CY2021Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
138000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4266000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4720000
CY2022Q2 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
4634000
CY2021Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
6120000
CY2022Q2 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
4353000
CY2021Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
7113000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2478000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1265000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
82223000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91003000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150347467
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150347467
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24852000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28331000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50597000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50423000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7812982
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1110439
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
59.67
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
652333
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
31.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
469439
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
76.85
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7801649
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
59.36
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4746997
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
47.11
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7801649
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
59.36
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
142700000
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.034
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.027
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4700000
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.007
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-185834000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
759225000
us-gaap Net Income Loss
NetIncomeLoss
-365051000
us-gaap Net Income Loss
NetIncomeLoss
646062000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77513327
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75826594
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77306970
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75418160
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77513327
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80449956
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77306970
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80458855
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.40
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
10.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.57
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.40
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.03
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8912465
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2332647
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8912465
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1694486
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9700000

Files In Submission

Name View Source Status
crsp-20220630_htm.xml Edgar Link completed
0000950170-22-015256-index-headers.html Edgar Link pending
0000950170-22-015256-index.html Edgar Link pending
0000950170-22-015256.txt Edgar Link pending
0000950170-22-015256-xbrl.zip Edgar Link pending
crsp-20220630.htm Edgar Link pending
crsp-20220630.xsd Edgar Link pending
crsp-ex10_1.htm Edgar Link pending
crsp-ex10_2.htm Edgar Link pending
crsp-ex31_1.htm Edgar Link pending
crsp-ex31_2.htm Edgar Link pending
crsp-ex32_1.htm Edgar Link pending
crsp-20220630_cal.xml Edgar Link unprocessable
crsp-20220630_def.xml Edgar Link unprocessable
crsp-20220630_lab.xml Edgar Link unprocessable
crsp-20220630_pre.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable